Literature DB >> 31680292

Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid.

John E Eaton1, Raj Vuppalanchi2, Rajender Reddy3, Sanjaya Sathapathy4, Bilal Ali5, Patrick S Kamath1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31680292     DOI： 10.1002/hep.31017

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  11 in total

Review 1.  Farnesoid X receptor: a potential therapeutic target in multiple organs.

Authors:  Chao Zhang; Zixuan Wang; Qingqing Feng; Wei-Dong Chen; Yan-Dong Wang
Journal:  Histol Histopathol       Date:  2021-01-04       Impact factor: 2.303

2.  Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis.

Authors:  Joseph Carpenter; Gang Wu; Ying Wang; Erica M Cook; Tao Wang; Doree Sitkoff; Karen A Rossi; Kathy Mosure; Xiaoliang Zhuo; Gary G Cao; Milinda Ziegler; Anthony V Azzara; Jack Krupinski; Matthew G Soars; Bruce Alan Ellsworth; Dean A Wacker
Journal:  ACS Med Chem Lett       Date:  2021-08-05       Impact factor: 4.632

3.  Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice.

Authors:  Chuangzhen Lin; Bingqing Yu; Lixin Chen; Zhaohui Zhang; Weixiang Ye; Hui Zhong; Wenke Bai; Yuping Yang; Biao Nie
Journal:  Front Pharmacol       Date:  2022-05-09       Impact factor: 5.988

4.  Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis.

Authors:  Binu V John; Kaley Schwartz; Cynthia Levy; Bassam Dahman; Yangyang Deng; Paul Martin; Tamar H Taddei; David E Kaplan
Journal:  Hepatol Commun       Date:  2021-05-06

5.  Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.

Authors:  Binu V John; Nidah S Khakoo; Kaley B Schwartz; Gabriella Aitchenson; Cynthia Levy; Bassam Dahman; Yangyang Deng; David S Goldberg; Paul Martin; David E Kaplan; Tamar H Taddei
Journal:  Am J Gastroenterol       Date:  2021-09-01       Impact factor: 12.045

6.  Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling.

Authors:  Vik Meadows; Lindsey Kennedy; Burcin Ekser; Konstantina Kyritsi; Debjyoti Kundu; Tianhao Zhou; Lixian Chen; Linh Pham; Nan Wu; Jennifer Demieville; Laura Hargrove; Shannon Glaser; Gianfranco Alpini; Heather Francis
Journal:  Hepatology       Date:  2021-09-09       Impact factor: 17.298

7.  Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis.

Authors:  Surain B Roberts; Marwa Ismail; Gowthami Kanagalingam; Andrew L Mason; Mark G Swain; Catherine Vincent; Eric M Yoshida; Cynthia Tsien; Jennifer A Flemming; Harry L A Janssen; Gideon M Hirschfield; Bettina E Hansen; Aliya F Gulamhusein
Journal:  Hepatol Commun       Date:  2020-07-06

Review 8.  Emerging therapies for PBC.

Authors:  David Maxwell Hunter Chascsa; Keith Douglas Lindor
Journal:  J Gastroenterol       Date:  2020-01-22       Impact factor: 7.527

Review 9.  Update on Emerging Treatment Options for Primary Biliary Cholangitis.

Authors:  Maria T Aguilar; David M Chascsa
Journal:  Hepat Med       Date:  2020-05-25

Review 10.  Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases.

Authors:  Vik Meadows; Lindsey Kennedy; Debjyoti Kundu; Gianfranco Alpini; Heather Francis
Journal:  Front Med (Lausanne)       Date:  2020-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.